CeNeRx BioPharma Announces Successful Completion Of Phase L Clinical Program For Novel Antidepressant Agent Tyrima(TM)

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, announced the successful completion of the Phase l clinical program for Tyrima(TM), its lead candidate for the treatment of depression and anxiety. Tyrima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A.

More: continued here

Filed under: Depression on January 29th, 2008